MSI-L

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Retrieved on: 
목요일, 5월 30, 2024
ICI, Patient, Liver disease, Pembrolizumab, Ovarian cancer, TME, Colorectal cancer, MSI-L, ECM, Safety, Diarrhea, MSS, PRS, Assistant, Cancer, Infiltration, ASCO, CRC, Fatigue, Society, Aes, Immunotherapy, DCR, Annual general meeting, Johns Hopkins, Pharmaceutical industry

The poster presentation highlights the safety and tolerability of doses between 30-200 mg of NC410 in combination with 400 mg of pembrolizumab.

Key Points: 
  • The poster presentation highlights the safety and tolerability of doses between 30-200 mg of NC410 in combination with 400 mg of pembrolizumab.
  • The combination resulted in partial responses (PR) and stable disease in both CRC and ovarian cancer.
  • “While MSS/MSI-L CRC and ovarian cancer are difficult to treat and recalcitrant to immunotherapy, the combination of NC410 and pembrolizumab demonstrated clinical activity against both tumor types.
  • Details of the presentation are as follows:
    Title: A Phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Retrieved on: 
수요일, 4월 24, 2024
Cancer, MSS, Poster, Colorectal cancer, Johns Hopkins, CRC, MSI-L, ICI, ASCO, Society, Assistant, Annual general meeting, Ovarian cancer

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.

Key Points: 
  • BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.
  • Title: A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer